Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers

por Adam J. Davenport, Ioana Neagoe, Nico Bräuer, Markus Koch, Andrea Rotgeri, Jens Nagel, Alexis Laux-Biehlmann, Frederic Machet, Anne-Marie Coelho, Susan Boyce, Nikisha Carty, Mark J. Gemkow, Stephen D. Hess, Thomas M. Zollner, Oliver M. Fischer
Publicado 2021